Core Viewpoint - The company anticipates a significant net loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -288 million to -380 million yuan, indicating a continuation of losses compared to the previous year [1][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -295 million to -387 million yuan [3]. Group 2: Previous Year’s Performance - In the previous year, the total profit was -85.43 million yuan, with a net profit attributable to shareholders of -86.69 million yuan [5]. - The net profit attributable to shareholders, after excluding non-recurring gains and losses, was -94.33 million yuan [5]. - The earnings per share for the previous year were -0.0512 yuan [6]. Group 3: Reasons for Expected Loss - The medical services segment is experiencing losses due to high fixed costs and low gross margins from drug and consumable sales, despite a revenue increase of approximately 60% compared to the previous year [7]. - The coal business is facing losses due to reduced effective mining time and increased costs, alongside a decline in coal sales prices [7]. - The chemical business is impacted by reduced production and increased maintenance costs due to a major overhaul in 2025, leading to decreased net profit [7]. Group 4: Non-Operating Gains and Losses - The non-operating gains and losses for the reporting period include government subsidies and other net income of 3.4879 million yuan [8]. Group 5: Additional Notes - The performance forecast data is preliminary and has not been audited by registered accountants; the final figures will be disclosed in the audited annual report for 2025 [4][10].

Core Viewpoint - The company, Chitianhua (600227.SH), has announced an expected net loss of 280 million to 380 million yuan for the year 2025, indicating a continuation of losses compared to the previous year [1] Summary by Relevant Sections Medical Services Segment - The medical services segment is experiencing losses due to the early development stage of its hospitals. Although revenue has increased by approximately 60% year-on-year, a significant portion of this revenue comes from pharmaceuticals and consumables, which have no profit margin, resulting in low gross profit for the hospitals. Additionally, high fixed costs such as labor and depreciation, along with ongoing market and reputation cultivation, contribute to the continued losses [1] Coal Business Segment - The coal business is facing losses due to several factors: 1. Anjia Mining's production system equipment upgrades, gas management projects, and regional safety management have reduced effective mining time, leading to lower raw coal output and higher overall costs [1] 2. A decline in coal sales prices [1] 3. In accordance with accounting prudence principles, the company is conducting impairment tests on long-term assets showing signs of impairment, which is expected to result in impairment provisions [1] Chemical Business Segment - The chemical business segment has seen a decrease in net profit year-on-year due to reduced production and revenue from a major overhaul in 2025, coupled with increased maintenance costs [1]

(一)主营业务影响:1.医疗服务业务板块亏损因素：公司旗下医院尚处于发展初期，虽然营业收入较上年 同期增长约60%，但营业收入中药品、耗材收入占比较大，药品、耗材无利润，导致医院毛利较低，加 之仍处于市场、口碑培育期，人力成本、折旧等固定成本摊销较高等因素，致医院仍处于亏损阶段。2. 煤炭业务板块亏损因素：(1)安佳矿业2025 年受生产系统设备改造、瓦斯治理工程施工、区域性安全管 理等因素影响有效开采时间，致原煤产量偏低，综合成本偏高。(2)煤炭销售单价下降。(3)根据《企业 会计准则》及公司会计政策的相关规定，基于会计谨慎性原则，审慎反映资产质量，对存在减值迹象的 长期资产进行减值测试，预计计提减值准备。3.化工业务板块：因2025年停产大修致产量减少，收入减 少，大修费用增加，导致桐梓化工净利润同比上期减少。(二)非经营性损益的影响:本报告期非经营性损 益影响主要是取得的政府补助及其他营业外收支净收益348.79万元。 本期业绩预亏的主要原因: 格隆汇1月29日丨赤天化(600227.SH)公布，预计2025 年年度实现归属于母公司所有者的净利润为-2.88 亿元到-3.8亿元，与上年同期(法定披露数据 ...

证券代码:600227 证券简称:赤 天 化 编号:2026-006 （一）业绩预告期间 贵州赤天化股份有限公司 2025 年 1 月 1 日至 2025 年 12 月 31 日。 2025 年年度业绩预亏公告 （二）业绩预告情况 经财务部门初步测算，预计 2025 年年度实现归属于母公司所有 者的净利润为-28,800 万元到-38,000 万元，与上年同期（法定披露 数据）相比，将出现连续亏损。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、本期业绩预告情况 预计 2025 年年度实现归属于母公司所有者的扣除非经常性损益 后的净利润为-29,500 万元到-38,700 万元。 业绩预告的具体适用情形：净利润为负值。 业绩预告相关的主要财务数据情况：预计 2025 年年度实现归 属于母公司所有者的净利润为-28,800 万元到-38,000 万元， 与上年同期（法定披露数据）相比，将出现连续亏损。 本次业绩预告未经审计，仅为初步核算数据，具体准确的财 务数据以公司正式披露的经审计后的 2025 年年度 ...

Core Viewpoint - The company, Chitianhua, is expected to report a net loss attributable to shareholders of the parent company ranging from -288 million to -380 million yuan for the year 2025, indicating a continuation of losses [1] Financial Performance - The net profit for the same period last year was -86.6935 million yuan [1] - The net profit after deducting non-recurring gains and losses is projected to be between -295 million and -387 million yuan [1] Business Segment Analysis - The medical services segment saw a revenue increase of approximately 60%, but the pharmaceutical and consumables sectors reported no profit and high costs, contributing to the overall loss [1] - The coal business faced losses due to low production, decreased prices, and impairment provisions [1] - The chemical industry segment experienced reduced income and increased expenses due to a major overhaul, leading to a year-on-year decrease in net profit [1] Non-Operating Income - The company reported a net gain of 3.4879 million yuan from non-operating income [1]

南财智讯1月29日电，赤天化发布业绩预亏公告，预计2025年年度实现归属于母公司所有者的净利润 为-28,800万元到-38,000万元，与上年同期（法定披露数据）相比，将出现连续亏损。业绩预亏的主要 原因：（一）主营业务影响：1.医疗服务业务板块亏损因素：公司旗下医院尚处于发展初期，虽然营业 收入较上年同期增长约60%，但营业收入中药品、耗材收入占比较大，药品、耗材无利润，导致医院毛 利较低，加之仍处于市场、口碑培育期，人力成本、折旧等固定成本摊销较高等因素，致医院仍处于亏 损阶段；2.煤炭业务板块亏损因素：（1）安佳矿业2025年受生产系统设备改造、瓦斯治理工程施工、 区域性安全管理等因素影响有效开采时间，致原煤产量偏低，综合成本偏高；（2）煤炭销售单价下 降；（3）根据《企业会计准则》及公司会计政策的相关规定，基于会计谨慎性原则，审慎反映资产质 量，对存在减值迹象的长期资产进行减值测试，预计计提减值准备；3.化工业务板块：因2025年停产大 修致产量减少，收入减少，大修费用增加，导致桐梓化工净利润同比上期减少。（二）非经营性损益的 影响：本报告期非经营性损益影响主要是取得的政府补助及其他营业外收支净收益 ...

Group 1 - The agricultural chemical sector increased by 0.77% on January 26, with Chengxing Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Notable gainers in the agricultural chemical sector included Chengxing Co., Ltd. and Zhongnong United, both rising by 10.01% [1] Group 2 - The agricultural chemical sector experienced a net outflow of 40.45 million yuan from institutional investors, while retail investors saw a net inflow of 172 million yuan [2] - The top individual stock performers in terms of net inflow included Yuntianhua with a net inflow of 150 million yuan [3] - The overall trading volume and turnover for the agricultural chemical sector were significant, with Chengxing Co., Ltd. achieving a turnover of 7.53 billion yuan [1][2]

贵州赤天化股份有限公司 GUIZHOU CHITIANHUA CO.,LTD. 2026 年第一次临时股东会 会议资料 二〇二六年一月 | 序号 | | 会 | 议 | 议 | 程 | | --- | --- | --- | --- | --- | --- | | 1 | 宣布股东会开幕 | | | | | | 2 | 宣布到会股东人数及代表股份数 | | | | | | 3 | 审议《关于预计 2026 年度日常关联交易的议案》 | | | | | | 4 | 对上述议案进行表决并宣布表决结果 | | | | | | 5 | 股东会见证律师对本次股东会出具法律意见书 | | | | | | 6 | 会议闭幕 | | | | | 贵州赤天化股份有限公司 2026 年第一次临时股东会现场会议议程 贵州赤天化股份有限公司 2026 年第一次临时股东会会议资料 会议时间：2026 年 1 月 30 日下午 14:00 会议地点：贵州省贵阳市阳关大道 28 号赤天化大厦 22 楼会议室 主 持 人：董事长丁林洪 贵州赤天化股份有限公司 2026 年第一次临时股东会会议资料 关于预计 2026 年度日常关联交易的议案 ...

Group 1 - The company has not established a financial shared service center [1] - An investor inquired about the existence and establishment year of a financial shared service center [3] - The investor also asked about the technological tools used in the center and its digitalization score [3]

Group 1 - The core point of the announcement is the resolutions made during the 20th meeting of the 9th Board of Directors of Guizhou Chitianhua Co., Ltd, which includes the approval of expected related party transactions for 2026 and the convening of the first extraordinary shareholders' meeting in 2026 [1][3][4] Group 2 - The board meeting was held on January 14, 2026, with all 9 directors participating, and the procedures complied with relevant laws and regulations [2] - The board approved the proposal regarding expected related party transactions for 2026, which requires further approval from the shareholders' meeting [3][8] - The board also approved the proposal to convene the first extraordinary shareholders' meeting of 2026, with unanimous support from all directors present [4] Group 3 - The expected related party transactions for 2026 are necessary for the smooth operation of the company and adhere to principles of fairness and voluntary participation, ensuring no harm to the interests of the company and its shareholders [7][31] - The company plans to purchase products and services from related parties, including approximately 60.02 million yuan for medical supplies and 4 million yuan for land lease from its controlling shareholder [25][26] - The pricing for these transactions will be based on fair market principles, ensuring that the interests of all shareholders are protected [28][30] Group 4 - The first extraordinary shareholders' meeting is scheduled for January 30, 2026, and will utilize both on-site and online voting methods [34][35] - The meeting will address various proposals, including those requiring the abstention of related shareholders from voting [39]